In this podcast Novo Nordisk researcher Dr. Kajsa Kvist and Dr. John Buse from the University of North Carolina at Chapel Hill (UNC Health) discuss how and why Novo Nordisk became an early participant of the National COVID-19 Collaborative (N3C), as a tool to study the pandemic. The Novo Nordisk patient analytics team led by Dr. Kvist is studying how COVID-19 affects patients with diabetes to learn how their products can help infected patients. The collaborators discuss the working model they established to leverage the strengths of academic and industry partners through the N3C.